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Summary Thirty-one consecutive patients with advanced epithelial ovarian cancer entered a phase II study
with cisplatin and etoposide combination chemotherapy. None of them had received prior chemotherapy or
radiotherapy. Most patients had advanced (88%) or far advanced (61%) disease. All 31 patients are evaluable
for toxicity which was significant and led to removal of five (16%) patients from the study. Of the 23 patients
evaluable for response there were four clinical complete (CR) and eight partial (PR) responders for a total
clinical response rate of 52% of evaluable patients and 39% of all patients. Eight patients (four clinical CR
and four good PR) have undergone second look laparotomy with pathological CR in one of the clinical CR
patients. Median survival time for responders and non-responders is 19 and 8 months respectively. The results
obtained appear to be inferior to other cisplatin based combinations. Although this could be attributed to the
unusually high proportion of patients with bulky disease and stage IV patients, we feel that the study suggests
that etoposide did not add any benefits for this patient population to cisplatin as a single agent.
Since the introduction of cisplatin either singly or in com-
bination with other agents in the treatment of the common
epithelial ovarian cancers some improvement was seen
mainly in terms of higher complete response rates and pos-
sibly longer survival compared with non-cisplatin
chemotherapy (Neijt et al., 1984; Edwards et al., 1983). On
the other hand, despite great efforts, no progress has been
made in the past years towards further increases in CR rates
or survival and there is an apparent plateau in the
therapeutic results for advanced disease.
The present study was conducted to evaluate the
antitumour activity and toxicity of the cisplatin-etoposide
combination. We incorporated etoposide in a first line com-
bination because it has not been evaluated yet as a first line
treatment in ovarian cancer although studies of etoposide
either singly or in combination as second or third line treat-
ment have been somewhat encouraging with 7-29% partial
remissions and some 10% complete remissions (Junji, 1982;
Dittrich et al., 1986; Kuhnle et al., 1987; De Lena et al.,
1986). It also seemed possible that the synergistic effects of
these drugs in other forms of cancer could prove advan-
tageous in ovarian cancer patients (Hainsworth et al., 1985;
Einhorn, 1986). This paper reports the results of this phase II
study.
Patients and methods
Before entry a written informed consent was obtained from
each patient. The following eligibility criteria were used for
entry in the study: histological documentation of common
epithelial ovarian carcinoma; no prior chemotherapy or
radiotherapy; age <75 years; FIGO stage>Ic; ECOG perfor-
mance status (PS) <3; predicted survival>2 months; nor-
mal renal and liver function tests (creatinine clearance, BUN,
LFTs); and no serious concurrent medical illness.
Treatment schedule was as follows: etoposide 100 mg m-2
in 250 ml NS was given as an i.v. infusion over 30 min on
days 1, 2 and 3. Then the patient was hydrated overnight
with 2 1 of equal parts of NS and 5% dextrose solution
(DW5) with 20 mEq KC 1' and on the morning of day 4
cisplatin 100 mg m-2 was administered as a short i.v. infusion
in 20 min. Mannitol (12 g) i.v. bolus and vigorous post-
hydration with NS and DW5 was given at a rate of 3 1 m-2
24h-' over the following 24 h.
Standard antiemetic therapy with metoclopramide and
dexamethasone was administered to all patients. This con-
sisted of 2 mg kg-' metoclopramide given as a rapid infusion
over 15 min half an hour before cisplatin administration and
followed by four doses every 90 min thereafter. Dex-
amethasone 20 mg was given as an i.v. bolus injection 3 h
before the administration of cisplatin and every 3 h
thereafter, for a total of four doses.
Treatment was repeated every 3 weeks. Drug administra-
tion was delayed until the platelet and WBC count were
> 130 x i0 l-'I and 14 x i03 1-' respectively or the
creatinine clearance was >50 ml min '. Delays up to 2
weeks were allowed, beyond which patients were withdrawn
from the study. If haematological and renal toxicity were not
encountered a 10% increase of both drugs was made for the
second and third courses up to a final dose of 120 mgm2
for etoposide and cisplatin. Dose reduction was made ac-
cording to haematological toxicity of the preceding course of
therapy as follows: a 20% dose reduction for both drugs was
made for a platelet or WBC nadir of <60 x 103y Ll- or
1.5 x 103 gl.-' and 40% for a platelet or WBC nadir
<25 x 1031l-1 or 1.0 x 103,h'- .
All patients had initially undergone exploratory
laparotomy for diagnosis and cytoreduction. Total ab-
dominal hysterectomy, salpingoophorectomy and omentec-
tomy with peritoneal washings and scrapings of the diag-
phragm for cytology were carried out in 11 patients whereas
the rest had lesser cytoreduction because of the extent of
their abdominopelvic disease. All patients had pelvic,
paraaortic and liver ultrasound scans before starting
chemotherapy and these were repeated every other course
until the end of the treatment programme. Abdominal CT
scans were done routinely before the third and sixth courses
of chemotherapy. Eleven patients referred to our department
from other institutions had this procedure done before the
initial laparotomy as preoperative staging. Seven patients
with widespread liver and lung metastases had careful
preoperative exploration of the gastrointestinal system by
means of endoscopy (gastroscopy-colonoscopy).
Full blood count, platelet count, BUN, creatinine
clearance, liver function tests, serum CA-125 and CEA
estimations were done before each course; full blood count,
platelet count, BUN and serum creatinine on day 10; chest
X-ray every other course, except for patients with lung
disease in whom chest X-ray was performed in every course.
Liver ultrasound scans were carried out in every course in
patients with liver metastases. Thorough clinical examina-
tions under anaesthesia (first and sixth courses) and without
anaesthesia (in between courses) were performed by two
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doctors independently. Patients were evaluated for response
every month. If no objective response was detectable after
three courses or if progression occurred at any time the
therapy was discontinued and patients received other treat-
ment. If clinical response was achieved treatment continued
for a total of six courses.
Second look laparotomy followed in patients with clinical
complete response or if post-therapy clinical examination and
CT scans suggested the presence of residual tumour that
could be removed surgically. If pathological complete res-
ponse was documented the patients entered a follow-up pro-
gramme; otherwise they continued treatment with other
drugs.
World Health Organization (WHO) criteria were used for
response and toxicity. Survival curves were constructed ac-
cording to the Kaplan-Meier method and comparison of
survival was done by the log rank test.
Results
Between August 1986 and September 1987, 31 consecutive
patients entered the study. All patients were evaluable for
toxicity, 26 for survival (excluded from survival figures are
five patients withdrawn from the study following the first
course of treatment because of toxicity) and 23 are evaluable
for response (the three Ic patients were not evaluable). No
patient was lost to follow-up. Patient characteristics are
shown in Table I. There was a high proportion (30%) of very
advanced stage IV disease (two with wide spread lung and
seven with multiple haematogenous liver metastases) and also
a high (88%) proportion of bulky (>2 cm) or very bulky
(>10 cm, 61%) residual disease in those patients with cancer
confined in the abdominal cavity.
Four (17%) CRs and eight (35%) PRs were observed for a
total clinical response rate of 52% of evaluable patients or
39% of the whole group (Table II). In the remaining 11
patients therapy was discontinued after two courses because
of progression (nine patients) and after three courses because
of absence of signs of objective response (two patients) ac-
cording to the protocol. These patients were offered a variety
of chemotherapy regimes that included systemic or int-
raperitoneal chemotherapy.
Of the CRs one was seen in a patient with 3 cm residual
disease and three in patients with > 1O cm.
Patients with liver and lung involvement all failed to respond
to chemotherapy. No differences in response were found with
regard to histological subtype, grade and age.
Toxic effects observed during this trial are summarized in
Table III. There were no toxicity related deaths. Toxicity
consisted mainly of myelosuppression, nausea/vomiting and
alopecia. Grade 1 and 2 nephrotoxicity occurred in seven
patients but it was transient and did not result in treatment
delays.
However, one patient developed irreversible renal damage
after the sixth course. Five patients required blood and one
patient required a platelet transfusion. Febrile episodes
associated with neutropenia occurred in three patients and were
successfully treated with broad spectrum antibiotics. Of the
total of 114 administered courses, nine (8%) were delayed for a
median of8.2 days because ofmyelosuppression. All seventeen
patients receiving three (two patients with stable disease) or six
Table I Patient characteristics
Characteristics No. ofpatients (%)
Total 31
Age (years)
Mean 57
Median 59
Range 24-74
ECOG performance status
0 4(13)
1 13 (42)
2 9 (29)
3 5 (16)
FIGO stage
Ica 3 (9)
III 19 (61)
IV 9 (30)
Grade
I 7 (23)
II 10 (32)
III 14 (45)
Histology
Serous 8 (26)
Mucinous 6 (19)
Endometrioid 3 (10)
Undifferentiated 14 (45)
Residual disease (cm)
Abdominal
0 4(13)
2-5 3 (10)
5-10 5 (16)
>10 19 (61)
Liver haematogenous 7 (24)
Lung parenchymal 2 (6)
aAll with positive cytology.
(15 patients with clinical response) reached the predicted
maximal escalation dose of 120 mg m-' for both drugs.
Five patients were removed from the study because of
toxicity; one with debilitating neurotoxocity after the first cycle
and four with acute vasomotor reactions on first contact with
etoposide. This unexpected side-effect consisted of hyperten-
sion, tachycardia, sweating and discomfort appearing in less
than a minute from the start ofthe drug infusion and lasting for
20-30 min. Corticosteroids were administered in all four cases.
Readministration was not attempted because of the patient's
refusal. (Athanassiou et al., 1988). All five withdrawn patients
had stage III disease, median age 61 and PS 1. One ofthem had
no residual disease after the initial operation, three had 2-5 cm
and one 5-10 cm residuals. In particular there was no liver or
lung involvement, no history of past or concurrent medical
illness and no history of allergy.
Second look operation was carried out in eight complete or
good partial responders after six courses of chemotherapy
(Table IV). Pathological CR was documented in one (25%) of
the four patients with clinical CR. This patient had > 10 cm
residualdisease onstartingchemotherapy. Completeexcisionof
disease found at second look was possible in three (43%) of
seven pathological partial responders.
At the time of analysis (4 September 1988) 13/26 (50%)
patients are alive and 13/26 (50%) have died (Figure 1). Ofthe
13 survivors, seven are alive and offtreatment with no evidence
Table II Clinical response (WHO criteria) in relation to stage
Allpatients (n = 31) Evaluable patients (n = 23)
Stage CR(%) PR(%) TRR (%) CR(%) PR(%) TRR(%)
Ic (3pts) - - (Opts) - -
III (19pts) 4 (21) 8 (42) 12 (63) (14pts) 4 (29) 8 (57) 12 (86)
IV (9pts) - - - (9pts) - _ _
Total (31pts) 4 (13) 8 (26) 12 (39) (23pts) 4 (17) 8 (35) 12 (52)
95% CI 1.2-24 10-41 22-55 1.9-32.8 15-50.5 31.6-72.4
CR, complete response; PR, partial response; TRR, total response rate; 95% CI, 95% confidence interval.CISPLATIN AND ETOPOSIDE IN OVARIAN CANCER 757
ofdisease although followupis less than 2 years forallpatients.
This group includes the three patients with stage Ic disease, the
one patient who achieved pathological CR and the three
patients with pathological partial response where the residual
disease found at second look laparotomy was completely
resected. Six patients with partial response and with either
incomplete debulking at second look or no second look at all
survive on other treatment. Median survival time (MST) for all
patients from starting treatment is 16 months (range 2-25 +).
MST for complete responders and those with stage Ic disease is
22 + months (range 16-25 +), for partial responders 15.5
months (8-22 +) and for those with stable or progressive
disease 8 months (2-15). Median relapse-free interval for
responders and for those with stage Ic disease is 16.5 months
(7-25 +). Median follow-up period for all patients from
starting treatment is 16 months (range 2-25 +).
Table III Toxicity in 31 patients (WHO scale)
Grade
0 I II III IV
Leukopenia 10 6 8 6 1
Thrombocytopenia 20 8 2 0 1
Anaemia 8 14 5 1 3
Nausea/vomiting 5 3 4 16 3
Alopecia 0 0 13 18 0
Nephrotoxicity 24 4 3a 0 0
Neurotoxicity 25 5 0 lb 0
Postural hypotension 3 patients
Acute vasomotor reaction to etoposide 4 patientsb
aOne irreversible after the 6th cycle; bremoved from the study.
Table IV Second look operation in eight patients
Residual disease Clinical Pathological Disease Complete
No. ofpatients on starting chemo. (cm) response response found (cm) excision
1 2-5 CR PR 2-5 No
2 >10 CR CR 0 -
3 >10 CR PR 2-5 Yes
4 >10 CR PI <2 No
5 >10 PR PR 5-10 No
6 >10 PR PR 5-10 No
7 5-10 PR PR <I Yes
8 2-5 PR PR <I Yes
Three stage Ic patients with pathologically negative second look are not included in this group.
1.0
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cn20.6.
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Figure 1 Survival of 26 patients to 4 September 1988.
Discussion
These response rates are lower than those generally reported
with other cisplatin-based combinations (Neijt et al., 1987;
Thigpen & Blessing, 1985). One could argue that this could be a
result ofthe poor prognostic features ofthis group ofpatients.
However, even in this relatively small group ofpatients we feel
the results suggest that etoposide has probably not added to
cisplatin chemotherapy and should not be pursued as a front
line treatment for advanced ovarian cancer.
Results of second look laparotomy were similar to those
reported with other combinations (Ho et al., 1987; Copeland &
Gershenson, 1986). Toxicity in general was significant. Four
(13%) patients were removed from the study because of
etoposide acute vasomotor reactions; and one (3%) because of
severeneurotoxicity. Life threatening thrombocytopenia occur-
red in one (3%) patient and certainly the quality of life was
adversely affected in at least three (10%) patients with postural
hypotension. The mechanism of this symptom could well be
cisplatin induced autonomic neuropathy (Rosenfeld & Broder,
1984). No comments are possible on survival because longer
follow-up is needed. In our opinion, the cisplatin-etoposide
combination was only moderately effective and considerably
toxic to this treated group compared with other cisplatin-
containing combinations.
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